NPI: 1245759166 · CONCORD, NC 28025 · Pediatric Sports Medicine Physician · NPI assigned 09/12/2017
Authorized official RISSMILLER, SCOTT controls 20+ related entities in our dataset. Read more
| Authorized Official | RISSMILLER, SCOTT (ENTERPRISE EVP) |
| Parent Organization | CAROLINAS PHYSICIANS NETWORK INC |
| NPI Enumeration Date | 09/12/2017 |
Other providers sharing the same authorized official: RISSMILLER, SCOTT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 28,537 | $990K |
| 2019 | 29,880 | $1.21M |
| 2020 | 24,280 | $970K |
| 2021 | 73,808 | $1.61M |
| 2022 | 122,522 | $1.96M |
| 2023 | 135,020 | $1.76M |
| 2024 | 137,015 | $1.48M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 61,014 | 53,041 | $3.66M |
| 99199 | Unlisted special service, procedure or report | 296,458 | 187,555 | $1.58M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 10,684 | 8,616 | $882K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9,414 | 8,294 | $854K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8,239 | 7,201 | $739K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6,418 | 5,661 | $569K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 14,422 | 12,363 | $509K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 24,728 | 21,240 | $444K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2,438 | 2,018 | $212K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3,361 | 2,876 | $159K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,937 | 1,609 | $88K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,225 | 1,119 | $76K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 14,580 | 12,764 | $66K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,382 | 3,133 | $45K |
| 90474 | 1,273 | 1,055 | $22K | |
| 96127 | 4,254 | 3,689 | $16K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 425 | 352 | $16K |
| 99215 | Prolong outpt/office vis | 70 | 62 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1,720 | 1,558 | $8K |
| 90686 | 7,624 | 6,757 | $5K | |
| 90651 | 256 | 218 | $5K | |
| 92551 | 4,349 | 3,935 | $3K | |
| 99173 | 10,418 | 9,258 | $3K | |
| 90734 | 292 | 249 | $3K | |
| 83655 | 139 | 129 | $2K | |
| 80061 | Lipid panel | 69 | 67 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 31 | 21 | $992.14 |
| 87807 | 68 | 61 | $890.20 | |
| 0001A | 22 | 12 | $722.00 | |
| 90677 | 870 | 825 | $521.62 | |
| 90670 | 4,466 | 3,783 | $467.22 | |
| 96161 | 177 | 154 | $464.52 | |
| 96160 | 135 | 120 | $415.29 | |
| 99051 | 13 | 13 | $317.76 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 13 | 13 | $302.40 |
| 90716 | 561 | 506 | $249.82 | |
| 90707 | 563 | 509 | $145.70 | |
| 90723 | 2,600 | 2,190 | $114.05 | |
| 90647 | 2,427 | 2,102 | $87.52 | |
| 90656 | 608 | 579 | $39.10 | |
| 36415 | Collection of venous blood by venipuncture | 13 | 13 | $32.40 |
| 90633 | 757 | 703 | $32.22 | |
| 36416 | 465 | 363 | $25.29 | |
| 81003 | 13 | 13 | $16.68 | |
| 3074F | 6,248 | 5,696 | $0.00 | |
| 3008F | 1,890 | 1,823 | $0.00 | |
| 90680 | 1,769 | 1,492 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 154 | 133 | $0.00 |
| 90696 | 14 | 13 | $0.00 | |
| 91307 | 19 | 13 | $0.00 | |
| 1160F | 11,869 | 10,869 | $0.00 | |
| 3078F | 6,150 | 5,613 | $0.00 | |
| 1159F | 19,802 | 17,358 | $0.00 | |
| 90685 | 126 | 123 | $0.00 | |
| 99177 | 13 | 13 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 17 | 17 | $0.00 |